Clinical Trials
517 trialsA Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
National Cancer Institute (NCI)
SG-AAA-II-01
National Cancer Centre, Singapore
LIGHT
Sun Yat-sen University
RAIRI-NPC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
National Cancer Institute (NCI)
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
A Multicenter, Prospective, Phase III Clinical Study of Proton Intensity-modulated Radiotherapy Versus Photon Intensity-modulated Radiotherapy for Untreated Non-metastatic Nasopharyngeal Carcinoma
Guangzhou Concord Cancer Center
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
MRG003
Sun Yat-sen University
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
Sun Yat-sen University
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
Sun Yat-sen University
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
Sun Yat-sen University
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Sun Yat-sen University
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
Sun Yat-sen University
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients
Sun Yat-sen University
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Sun Yat-sen University
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
Sun Yat-sen University
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
Sun Yat-sen University
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
AK112
National University Hospital, Singapore
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
University of California, San Francisco
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
CIPN
Sun Yat-sen University
Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
EPoRN
Jiangxi Provincial Cancer Hospital
Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era
Sun Yat-sen University
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Emory University
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
Sun Yat-sen University
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
Sichuan Baili Pharmaceutical Co., Ltd.
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
National Cancer Centre, Singapore
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
Sun Yat-sen University
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
Fudan University
Light
Hunan Cancer Hospital
AlloNK1
Singapore General Hospital
MABEL
Baylor College of Medicine
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University